KRTL Teams Up With Yuhan To Develop Cannabinoid-Based Products For US And Korean Commercial Markets

KRTL International Corp and KRTL Biotech Inc., a wholly owned subsidiaries of KRTL Holding Group, Inc. (OTCPK:KRTL) have entered into a memorandum of understanding for the development of industry-differentiated commercial CBD and other cannabinoid based products with Yuhan Care, a subsidiary of Yuhan Corporation.

“We’re honored to have Yuhan Care engage with us at KRTL, they are a natural health care professionals inherited innovative research competence from Yuhan Corporation, 100-year-old company with a pristine reputation in Korea and around the world. Their commitment to quality and transparency is something we strive for at KRTL and a standard to be emulated by any in the pharmaceutical industry. This agreement allows KRTL to take an incredible strategic step toward our commercial efforts in Korea as the country progresses toward legalization based on the work in the Hemp Free Zone and allows a trusted and significant bridge for CBD products coming into the US from Korea – something that’s never been done before,” stated Kai Kim, CEO of KRTL International Corporation.

Under this memorandum of understanding , KRTL will develop joint cannabinoid-based products alongside Yuhan targeted at the US and Korean commercial markets, develop, distribution channels and partners, and collaborate on various R&D projects within the Korea Hemp Free Zone and throughout the US. This agreement outlines the exclusive utilization of KRTL’s CBD manufacturing partners which boast cGMP compliance, FDA approval, and certified ISO/IEC 17025 facilities based in the US, for the sole sourcing of cannabinoid-based products that emerge from this agreement.

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo: Benzinga; Sources: courtesy of jarmoluk and lindsayfox via Pixabay

Related News

CBD Training Academy Launching In South Korea